Glucagon-like peptide-1 receptor agonists in neoplastic diseases

被引：1
作者：
Ji, Lisan [1 ]
He, Xianzhen [2 ]
Min, Xinwen [1 ]
Yang, Handong [1 ]
Wu, Wenwen [3 ]
Xu, Hao [1 ]
Chen, Jun [1 ,4 ]
Mei, Aihua [1 ]
机构：
[1] Hubei Univ Med, Sinopharm Dongfeng Gen Hosp, Hubei Clin Res Ctr Hypertens, Hubei Key Lab Wudang Local Chinese Med Res, Shiyan, Peoples R China
[2] Hubei Univ Med, Renmin Hosp, Childrens Med Ctr, Shiyan, Hubei, Peoples R China
[3] Hubei Univ Med, Sch Publ Hlth, Shiyan, Hubei, Peoples R China
[4] Hubei Univ Med, Virol Key Lab Shiyan City, Shiyan, Peoples R China
来源：
FRONTIERS IN ENDOCRINOLOGY | 2024年 / 15卷
关键词：
GLP-1RA; tumor diseases; function; mechanism; agonists; PANCREATIC-CANCER CELLS; THYROID C-CELLS; DIABETES-MELLITUS; INSULIN-SECRETION; INHIBITS GROWTH; GLP-1; ANALOG; ACTIVATION; EXENDIN-4; RISK; APOPTOSIS;
D O I：
10.3389/fendo.2024.1465881
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Glucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing weight, and lowering blood lipids. It has also been shown that it can influence the proliferation and survival of cells and has a certain effect on the prognosis of some neoplastic diseases. In this study, the potential effects of GLP-1RAs on the occurrence and development of tumors were reviewed to provide new ideas for the prevention and treatment of tumors in patients.
引用
收藏
页数：9
相关论文
共 98 条
[31]   Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review [J].
Guo, Xia ;
Yang, Qing ;
Dong, Jianjun ;
Liao, Lin ;
Zhang, Weiwei ;
Liu, Fupeng .
CLINICAL DRUG INVESTIGATION, 2016, 36 (06) :433-441
[32]   Effects of insulin analogs and glucagon-like peptide-1 receptor agonists on proliferation and cellular energy metabolism in papillary thyroid cancer [J].
He, Liang ;
Zhang, Siliang ;
Zhang, Xiaowen ;
Liu, Rui ;
Guan, Haixia ;
Zhang, Hao .
ONCOTARGETS AND THERAPY, 2017, 10 :5621-5631
[33]   Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease [J].
He, Shun ;
Kahles, Florian ;
Rattik, Sara ;
Nairz, Manfred ;
McAlpine, Cameron S. ;
Anzai, Atsushi ;
Selgrade, Daniel ;
Fenn, Ashley M. ;
Chan, Christopher T. ;
Mindur, John E. ;
Valet, Colin ;
Poller, Wolfram C. ;
Halle, Lennard ;
Rotllan, Noemi ;
Iwamoto, Yoshiko ;
Wojtkiewicz, Gregory R. ;
Weissleder, Ralph ;
Libby, Peter ;
Fernandez-Hernando, Carlos ;
Drucker, Daniel J. ;
Nahrendorf, Matthias ;
Swirski, Filip K. .
NATURE, 2019, 566 (7742) :115-+
[34]   Exendin-4 does not modify growth or apoptosis of human colon cancer cells [J].
He Wenjing ;
Yu Shuang ;
Li Weisong ;
Xiao Haipeng .
ENDOCRINE RESEARCH, 2017, 42 (03) :209-218
[35]   No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial [J].
Hegedus, Laszlo ;
Sherman, Steven I. ;
Tuttle, R. Michael ;
von Scholten, Bernt J. ;
Rasmussen, Soren ;
Karsbol, Julie D. ;
Daniels, Gilbert H. .
DIABETES CARE, 2018, 41 (03) :620-622
[36]   Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis [J].
Hogan, A. E. ;
Tobin, A. M. ;
Ahern, T. ;
Corrigan, M. A. ;
Gaoatswe, G. ;
Jackson, R. ;
O'Reilly, V. ;
Lynch, L. ;
Doherty, D. G. ;
Moynagh, P. N. ;
Kirby, B. ;
O'Connell, J. ;
O'Shea, D. .
DIABETOLOGIA, 2011, 54 (11) :2745-2754
[37]   Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes [J].
Holman, Rury R. ;
Bethel, M. Angelyn ;
Mentz, Robert J. ;
Thompson, Vivian P. ;
Lokhnygina, Yuliya ;
Buse, John B. ;
Chan, Juliana C. ;
Choi, Jasmine ;
Gustavson, Stephanie M. ;
Iqbal, Nayyar ;
Maggioni, Aldo P. ;
Marso, Steven P. ;
Ohman, Peter ;
Pagidipati, Neha J. ;
Poulter, Neil ;
Ramachandran, Ambady ;
Zinman, Bernard ;
Hernandez, Adrian F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (13) :1228-1239
[38]   Epac:: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic β-cell [J].
Holz, GG .
DIABETES, 2004, 53 (01) :5-13
[39]   Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials [J].
Huang, Mengjie ;
Wei, Ribao ;
Wang, Yang ;
Su, Tingyu ;
Li, Qingping ;
Yang, Xi ;
Chen, Xiangmei .
ANNALS OF MEDICINE, 2017, 49 (07) :552-561
[40]   Type-II diabetes and pancreatic cancer:: a meta-analysis of 36 studies [J].
Huxley, R ;
Ansary-Moghaddam, A ;
de González, AB ;
Barzi, F ;
Woodward, M .
BRITISH JOURNAL OF CANCER, 2005, 92 (11) :2076-2083
12345678910